Sernova Biotherapeutics Inc
SVA.TO
TSX
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.06% | -20.38% | -20.57% | -17.82% | -10.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.86% | -53.84% | -49.66% | -51.24% | -57.84% |
| Operating Income | 44.86% | 53.84% | 49.66% | 51.24% | 57.84% |
| Income Before Tax | 10.35% | 55.68% | 55.33% | 46.41% | 64.09% |
| Income Tax Expenses | -- | -1,280.00% | -876.47% | -- | -- |
| Earnings from Continuing Operations | 11.22% | 57.06% | 56.48% | 46.13% | 63.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.22% | 57.06% | 56.48% | 46.13% | 63.73% |
| EBIT | 44.86% | 53.84% | 49.66% | 51.24% | 57.84% |
| EBITDA | 44.35% | 53.47% | 50.42% | 51.60% | 57.87% |
| EPS Basic | 17.28% | 58.20% | 58.26% | 50.28% | 66.53% |
| Normalized Basic EPS | 16.00% | 56.58% | 56.94% | 49.56% | 66.89% |
| EPS Diluted | 17.28% | 58.20% | 58.26% | 50.28% | 66.53% |
| Normalized Diluted EPS | 16.00% | 56.58% | 56.94% | 49.56% | 66.89% |
| Average Basic Shares Outstanding | 6.89% | 2.72% | 3.54% | 8.20% | 8.27% |
| Average Diluted Shares Outstanding | 6.89% | 2.72% | 3.54% | 8.20% | 8.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |